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Intensive vs. moderate lipid lowering with statins after acute coronary
syndrome
Cannon CP, Bromwald E, McCabe CH, et al. New Engl J Med 2004;350:
1495-504.
Conclusion: Patients with a recent acute coronary syndrome have
greater protection against major cardiovascular events and death when
treated with an intensive lipid-lowering statin regimen versus a standard
statin regimen.
Summary: The study enrolled 4,162 patients hospitalized for acute
coronary syndrome. Enrollment occurred within 10 days of hospitalization.
The patients received standard medical management including aspirin at
dosages of 75 to 325 mg daily with or without clopidogrel or warfarin. They
were randomized with a 1 to 1 allocation scheme to receive either 40 mg of
pravastatin daily (standard therapy) or 80 mg of atorvastatin daily (intensive
therapy). The primary end point was a composite of death from any cause,
unstable angina, myocardial infarction, stroke, and revascularization per-
formed at least 30 days after randomization. Follow-up was from 18 to 36
months (mean, 24 months).
Median low-density lipoprotein (LDL) cholesterol level achieved dur-
ing treatment was 95 mg/dL in the standard-dose pravastatin group and 62
mg/dL in the intensive-dose atorvastatin group (P  .001). The rates of
primary end points at 2 years determined by Kaplan-Meier estimates were
26.3% in the pravastatin group and 22.4% in the atorvastatin group; a 16%
decrease in the hazard ratio in favor of the intensive-therapy atorvastatin
group (P  .005; 95% confidence interval, 5-26%).
Comment: Previous studies have indicated standard dose statin ther-
apy is beneficial. The Heart Protection Study, in which statin treatment
resulted in an LDL cholesterol level that was 40 mg/dL lower than the
placebo group, was accompanied by 25% reduction in cardiovascular events.
This study demonstrates that even more intensive lipid lowering increases
benefit further. The implications are profound and the study likely marks a
new era of intensive statin therapy.
Sex differences in carotid plaque and stenosis
Iemolo F, Martiniuk A, Steinman DA, Spence JD. Stroke 2004;35:477-81.
Conclusion: Carotid plaque area is a greater predictor of stroke,
myocardial infarction, and death than carotid stenosis.
Summary: Experimental and epidemiologic evidence suggests estro-
gen may have beneficial effects on endothelial function and development of
atherosclerosis. This raises the possibility of sex differences in arterial remod-
eling. Sex differences were evaluated in carotid plaque area and stenosis with
respect to survival free of stroke, death, and myocardial infarction. The
authors studied 1,686 patients followed in a premature atherosclerosis and
stroke prevention clinic associated with the London Health Sciences Center
in London, Ontario, Canada. A total of 1,686 patients were followed
annually for up to 5 years (mean, 2.5  1.3 years). Carotid plaque area was
determined by using high-resolution duplex ultrasound. Carotid stenosis
was determined by Doppler peak frequency measurements calibrated against
angiography. Cardiovascular events were ascertained by questionnaire at
annual visits, by review of hospital charts, and by contact with families and
family physicians.
During follow-up, there were 45 strokes, 94 myocardial infarctions,
and 41 deaths. Carotid stenosis and plaque increased with age. Overall,
women had greater stenosis compared with men (P  .001), but men had
greater plaque area than women at all ages (P  .001). The combination of
stroke, myocardial infarction, and death in the total population was pre-
dicted by carotid artery plaque area (P  .004), but not by carotid artery
stenosis (P  .42). When sexes were analyzed separately, plaque area was a
significant predictor of stroke, myocardial infarction, or death for women
(P .028) and approached significance for men (P .06). Stenosis did not
predict the combined outcome of stroke, myocardial infarction, and death
for men (P  .84) or women (P  .20).
Comment: It is perplexing why stroke, myocardial infarction, and
death were not predicted by carotid stenosis. Perhaps carotid plaque area is
a better measure of the overall burden of atherosclerosis than carotid artery
stenosis. In that regard, it would have been interesting if the authors had
included other measures of atherosclerosis, such as the ankle brachial index,
in their study. The study raises the interesting question as to whether
vascular laboratories should consider measurement of total plaque burden
during assessment of the carotid bifurcation.
Factor V Leiden and the risk for venous thromboembolism in the adult
Danish population
Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Ann Intern Med
2004;140:330-7.
Conclusion: In patients with the Factor V Leiden genotype, smoking,
obesity and old age result in an absolute 10-year thromboembolic risk of
10% in heterozygotes and 51% in homozygotes.
Summary: The authors sought to determine hazard ratios for venous
thromboembolism (VTE) in Factor V Leiden heterozygotes and homozy-
gotes. In addition, they sought to determine whether hazard ratios differed
for deep venous thrombosis (DVT) or pulmonary embolism (PE), and to
estimate absolute risk for VTE according to Factor V Leiden genotype and
the presence, or absence, of other VTE risk factors. This was a cohort study
with 23 years of follow-up of 9,253 randomly selected individuals from the
adult Danish population. Hospitalization, death from VTE, Factor V Leiden
genotype, and additional thrombotic risk factors were assessed. Adjusted
hazard ratios in heterozygotes and homozygotes, compared with noncarri-
ers, were 2.7 (95% confidence interval [CI], 1.8-3.8) and 18 (CI, 4.1-41)
respectively for VTE overall. For DVT, adjusted hazard ratios in heterozy-
gotes and homozygotes compared with noncarriers were 2.4 (CI, 1.3-3.8)
and 22 (CI, 0-60). For PE, hazard ratios were 3.0 (CI, 1.7-4.9) for
heterozygotes and 11 (CI, 0-33) for homozygotes. The highest absolute
10-year VTE risk for heterozygotes was 10% (CI, 7%-14%) in smokers older
than 60 years of age with a body mass index of 30kg/m2. In homozygotic
smokers older than 60 years of age with body mass indexes above 30kg/m2,
the absolute 10-year VTE risk was 51%.
Comment: The article reinforces the fact that risk factors for VTE are
not linearly additive. Risk is basically exponential. Individual risk factors for
VTE somehow act in synergy with the overall risk in a patient, with multiple
risk factors for VTE being considerably higher than would be predicted by
the individual contribution of each risk factor.
C-Reactive protein and other circulating markers of inflammation in
the prediction of coronary heart disease
Danesh J, Phil D, Wheeler JG, et. al. New Engl J Med 2004;350:1387-97.
Conclusion: C-Reactive protein (CRP) is only a moderate predictor of
coronary heart disease. Established risk factors, such as increased total
cholesterol and cigarette smoking, are stronger predictors of coronary heart
disease.
Summary: CRP is an acute-phase reactant binding capsular pneumo-
coccal polysaccharide. It is a very highly sensitive marker of inflammation
and is principally produced in hepatocytes. Its expression is induced by
cytokines, especially interleukin-6. Recent publications have suggested CRP
is a strong marker for risk of coronary events (Circulation 2003;107:499;
New Engl J Med 1997;337:356).
This was a prospective study based in Reykjavik, Iceland. The authors
obtained information regarding CRP levels, erythrocyte sedimentation
rates, von Willebrand factor concentration, cholesterol levels, and cigarette
smoking in 2449 patients who had a non-fatal myocardial infarction or died
of coronary disease, and from 3969 controls without coronary disease. There
were a total of 18,569 participants in the study. Measurements were also
made in paired samples obtained from 379 participants an average of 12
years apart in order to quantify within-person fluctuations of inflammatory
marker levels.
The within-person correlation coefficient for long-term stability of
CRP values was 0.59, 95% confidence interval (CI), 0.52-0.66. This was
similar to blood pressure and total serum cholesterol. After adjusting for
baseline values of established risk factors, the odds ratio for coronary heart
disease was 1.45, 95% CI 1.25-1.68, comparing participants in the top third
of the group with respect to baseline CRP levels with those in the bottom
third. There were similar overall findings in an updated meta-analysis of
7068 patients with coronary heart disease. Compared with the association
between coronary heart disease and CRP, odds ratios in the Reykjavik study
were weaker for association of coronary heart disease with erythrocyte
sedimentation rate (1.30; 95% CI, 1.13-1.51) and von Willebrand factor
concentration (1.11; 95% CI, 0.97-1.27). Odds ratio for established risk
factors were stronger than that for CRP. The odds ratio for increased total
cholesterol concentration was 2.35 (95% CI, 2.03-2.74) while that for
cigarette smoking was 1.87 (95% CI, 1.62-2.16).
Comment: These findings confirm original work showing that CRP
levels are an indicator of increased risk for coronary heart disease. The
current findings do, however, call into question the magnitude of the risk. It
is not unusual for original publications to overestimate effects that are later
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